A Silicon Valley-based medical device company has developed an integrated cardiac diagnostics and remote monitoring platform combining ECG, phonocardiography (PCG), digital heart sounds and AI-assisted analysis across clinician and home-care settings.
The company’s commercial platform includes an FDA-cleared intelligent stethoscope with integrated ECG, with more than $1M in company-reported lifetime revenue and market validation across multiple geographies. Its primary growth focus is a next-generation multi-lead ECG + PCG remote monitoring device designed for hospital-to-home and longitudinal cardiac monitoring and currently advancing through the FDA pathway.
The technology is supported by a meaningful IP portfolio, clinical validation, proprietary signal-processing capabilities and AI-assisted analysis designed to support arrhythmia detection, murmur assessment and broader cardiac decision support.

Investment Highlights
1. FDA-cleared commercial cardiac device with integrated ECG
2. $1M+ company-reported lifetime revenue
Next-generation multi-lead ECG + PCG remote monitoring platform
3. AI-enabled cardiac analysis using synchronized ECG and heart-sound data
4. Established IP, clinical validation and regulatory experience
5. Potential alignment with existing diagnostic and RPM reimbursement pathways
6. Strategic fit for cardiac monitoring, patient monitoring, digital health and medtech platforms